N
RDY icon

Natixis’s Dr. Reddy's Laboratories RDY Stock Holding History

Natixis’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Buy
726
+61
+9% +$849 ﹤0.01% 1028
2025
Q4 		$9.34K Buy
665
+46
+7% +$645 ﹤0.01% 1052
2025
Q3 		$8.65K Sell
619
-3,302
-84% -$47.5K ﹤0.01% 995
2025
Q2 		$58.9K Sell
3,921
-102
-3% -$1.46K ﹤0.01% 869
2025
Q1 		$53K Sell
4,023
-332
-8% -$4.58K ﹤0.01% 827
2024
Q4 		$68.8K Hold
4,355
– – ﹤0.01% 866
2024
Q3 		$69.2K Buy
4,355
+1,520
+54% +$24.5K ﹤0.01% 769
2024
Q2 		$43.2K Hold
2,835
– – ﹤0.01% 793
2024
Q1 		$41.6K Hold
2,835
– – ﹤0.01% 832
2023
Q4 		$39.5K Hold
2,835
– – ﹤0.01% 844
2023
Q3 		$37.9K Hold
2,835
– – ﹤0.01% 841
2023
Q2 		$35.8K Sell
2,835
-720
-20% -$8.4K ﹤0.01% 866
2023
Q1 		$40.5K Buy
+3,555
New +$38.4K ﹤0.01% 845
2020
Q4 		– Sell
-196,000
Closed -$2.73M – 1096
2020
Q3 		$2.73M Sell
196,000
-389,110
-67% -$4.64M 0.02% 366
2020
Q2 		$6.2M Sell
585,110
-859,890
-60% -$8.75M 0.05% 256
2020
Q1 		$11.7M Sell
1,445,000
-666,300
-32% -$5.56M 0.09% 183
2019
Q4 		$17.2M Sell
2,111,300
-25,000
-1% -$197K 0.11% 206
2019
Q3 		$16.2M Buy
2,136,300
+28,075
+1% +$209K 0.1% 185
2019
Q2 		$15.8M Buy
+2,108,225
New +$16.6M 0.12% 161
2018
Q2 		– Sell
-34,885
Closed -$228K – 977
2018
Q1 		$228K Buy
+34,885
New +$244K ﹤0.01% 813
2017
Q4 		– Sell
-121,665
Closed -$868K – 1113
2017
Q3 		$868K Buy
+121,665
New +$875K 0.01% 534

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Natixis's RDY Position: Q1 2026 in Review

Natixis increased its Dr. Reddy's Laboratories (RDY) stake by 9.2% in Q1 2026, buying an estimated $849 and bringing the position to 726 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1028.

Natixis first reported a position in RDY in Q3 2017 and has held it in 21 quarters since. The position peaked at $17.2M in Q4 2019. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Natixis held 726 shares of Dr. Reddy's Laboratories worth $10.1K as of Q1 2026.
  • Natixis bought 61 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $849.
  • Dr. Reddy's Laboratories made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1028 holding.
  • Natixis first reported a position in Dr. Reddy's Laboratories in Q3 2017 and has held it in 21 quarters since.
  • Natixis's Dr. Reddy's Laboratories position peaked at $17.2M in Q4 2019.
  • 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.